Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering med...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798345/ https://www.ncbi.nlm.nih.gov/pubmed/33430860 http://dx.doi.org/10.1186/s12933-021-01213-w |
_version_ | 1783635043938205696 |
---|---|
author | Giugliano, Dario Longo, Miriam Scappaticcio, Lorenzo Caruso, Paola Esposito, Katherine |
author_facet | Giugliano, Dario Longo, Miriam Scappaticcio, Lorenzo Caruso, Paola Esposito, Katherine |
author_sort | Giugliano, Dario |
collection | PubMed |
description | Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i. |
format | Online Article Text |
id | pubmed-7798345 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77983452021-01-12 Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes Giugliano, Dario Longo, Miriam Scappaticcio, Lorenzo Caruso, Paola Esposito, Katherine Cardiovasc Diabetol Review Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i. BioMed Central 2021-01-11 /pmc/articles/PMC7798345/ /pubmed/33430860 http://dx.doi.org/10.1186/s12933-021-01213-w Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Giugliano, Dario Longo, Miriam Scappaticcio, Lorenzo Caruso, Paola Esposito, Katherine Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes |
title | Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes |
title_full | Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes |
title_fullStr | Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes |
title_full_unstemmed | Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes |
title_short | Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes |
title_sort | sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798345/ https://www.ncbi.nlm.nih.gov/pubmed/33430860 http://dx.doi.org/10.1186/s12933-021-01213-w |
work_keys_str_mv | AT giuglianodario sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes AT longomiriam sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes AT scappaticciolorenzo sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes AT carusopaola sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes AT espositokatherine sodiumglucosetransporter2inhibitorsforpreventionandtreatmentofcardiorenalcomplicationsoftype2diabetes |